IL-1β receptor antagonist reduces inflammation in hemodialysis patients.

Hung AM, Ellis CD, Shintani A, Booker C, Ikizler TA
J Am Soc Nephrol. 2011 22 (3): 437-42

PMID: 21310819 · PMCID: PMC3060437 · DOI:10.1681/ASN.2010070760

Chronic inflammation is highly prevalent in maintenance hemodialysis (MHD) patients and associates with increased mortality. IL-1β, a pro-inflammatory cytokine, is elevated in MHD patients. A balance between IL-1β and its naturally occurring antagonist may determine the inflammatory response and its consequences in this population. We performed a pilot randomized placebo-controlled trial to evaluate the efficacy of the administration of recombinant human IL-1 receptor antagonist (IL-1ra) on biomarkers of inflammation and nutrition in MHD patients with three consecutive high sensitivity C-reactive protein (hsCRP) measurements >5 mg/L. We randomly assigned 22 patients to placebo or IL-1ra (1:1) for 4 weeks; 14 completed the trial. Patients in the IL-1ra arm had a 53% reduction in mean hsCRP compared with 1% in the placebo arm (P = 0.008), a 40% reduction in mean IL-6 levels compared with a 20% increase in the placebo arm (P = 0.03), and a 23% increase in mean prealbumin compared with 6% in the placebo arm (P = NS). In conclusion, the administration of IL-1ra in MHD patients can lower biomarkers of inflammation. Whether IL-1ra administration improves survival in this population requires additional long-term studies.

MeSH Terms (19)

Adult Aged Biomarkers C-Reactive Protein Chronic Disease Double-Blind Method Female Humans Inflammation Interleukin-1beta Interleukin-6 Interleukin 1 Receptor Antagonist Protein Kidney Diseases Male Middle Aged Pilot Projects Receptors, Interleukin-1 Renal Dialysis Treatment Outcome

Connections (3)

This publication is referenced by other Labnodes entities:

Links